Olson J D, Arkin C F, Brandt J T, Cunningham M T, Giles A, Koepke J A, Witte D L
Department of Pathology, The University of Iowa College of Medicine, Iowa City 52242-1182, USA.
Arch Pathol Lab Med. 1998 Sep;122(9):782-98.
To review the state of the art as reflected in the medical literature and the consensus opinion of recognized experts in the field regarding the laboratory monitoring of unfractionated heparin therapy.
DATA SOURCES, EXTRACTION AND SYNTHESIS: The authors made an extensive review of the literature. The draft manuscript was circulated to every participant in the consensus conference prior to the convening of the conference. Extensive discussion concerning all of the issues addressed in the manuscript as well as the resulting recommendations occurred. This information was then used to revise the manuscript into its final form.
The resulting manuscript has 23 specific recommendations regarding preanalytic, analytic, and postanalytic phases of monitoring and testing for complications related to unfractionated heparin therapy. This report contains detailed discussion of these recommendations and includes literature citations that support them. A number of issues for which consensus could not be reached are also discussed. A method is provided to assist laboratories, particularly small laboratories, in providing clinicians with an appropriate therapeutic range for the activated partial thromboplastin time, the most commonly used test in monitoring heparin therapy.
回顾医学文献中所反映的最新技术水平以及该领域知名专家关于普通肝素治疗实验室监测的共识意见。
数据来源、提取与综合:作者对文献进行了广泛回顾。在共识会议召开之前,将手稿草案分发给了会议的每一位参与者。针对手稿中涉及的所有问题以及由此产生的建议进行了广泛讨论。然后利用这些信息将手稿修订为最终形式。
最终的手稿包含了23条关于普通肝素治疗监测及并发症检测的分析前、分析中和分析后阶段的具体建议。本报告包含了对这些建议的详细讨论,并列出了支持这些建议的文献引用。还讨论了一些未能达成共识的问题。提供了一种方法来帮助实验室,尤其是小型实验室,为临床医生提供活化部分凝血活酶时间(监测肝素治疗最常用的检测项目)的适当治疗范围。